What is HC Wainwright’s Estimate for MRNS FY2024 Earnings?

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) – Investment analysts at HC Wainwright boosted their FY2024 earnings estimates for shares of Marinus Pharmaceuticals in a report released on Thursday, November 14th. HC Wainwright analyst D. Tsao now expects that the biopharmaceutical company will post earnings of ($1.95) per share for the year, up from their previous forecast of ($2.00). HC Wainwright has a “Neutral” rating and a $2.00 price objective on the stock. The consensus estimate for Marinus Pharmaceuticals’ current full-year earnings is ($1.93) per share. HC Wainwright also issued estimates for Marinus Pharmaceuticals’ Q1 2025 earnings at ($0.18) EPS, Q2 2025 earnings at ($0.15) EPS, Q3 2025 earnings at ($0.13) EPS, Q4 2025 earnings at $0.04 EPS, FY2025 earnings at ($0.42) EPS, FY2026 earnings at ($0.26) EPS, FY2027 earnings at $0.14 EPS and FY2028 earnings at $0.54 EPS.

Several other equities analysts have also recently weighed in on the company. TD Cowen reaffirmed a “hold” rating on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. LADENBURG THALM/SH SH downgraded shares of Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 14th. Jefferies Financial Group restated a “hold” rating and issued a $0.50 target price (down from $5.00) on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $4.00 price target on shares of Marinus Pharmaceuticals in a report on Thursday. Finally, StockNews.com assumed coverage on shares of Marinus Pharmaceuticals in a research note on Sunday, November 10th. They issued a “hold” rating on the stock. Nine analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Marinus Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $4.79.

Marinus Pharmaceuticals Trading Down 2.2 %

NASDAQ MRNS opened at $0.30 on Monday. The company has a market cap of $16.66 million, a price-to-earnings ratio of -0.12 and a beta of 1.26. The company has a 50 day moving average of $1.22 and a 200-day moving average of $1.31. Marinus Pharmaceuticals has a 1-year low of $0.26 and a 1-year high of $11.26.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Suvretta Capital Management LLC grew its holdings in shares of Marinus Pharmaceuticals by 32.8% during the third quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock worth $8,930,000 after purchasing an additional 1,253,901 shares during the last quarter. Avoro Capital Advisors LLC grew its stake in shares of Marinus Pharmaceuticals by 31.4% in the first quarter. Avoro Capital Advisors LLC now owns 4,140,607 shares of the biopharmaceutical company’s stock worth $37,431,000 after purchasing an additional 990,607 shares during the last quarter. Vanguard Group Inc. increased its holdings in Marinus Pharmaceuticals by 5.0% in the first quarter. Vanguard Group Inc. now owns 2,805,920 shares of the biopharmaceutical company’s stock valued at $25,366,000 after purchasing an additional 132,689 shares during the period. abrdn plc raised its position in Marinus Pharmaceuticals by 146.1% during the 3rd quarter. abrdn plc now owns 2,658,527 shares of the biopharmaceutical company’s stock worth $4,679,000 after purchasing an additional 1,578,329 shares during the last quarter. Finally, GSA Capital Partners LLP lifted its holdings in Marinus Pharmaceuticals by 409.4% during the 3rd quarter. GSA Capital Partners LLP now owns 1,016,634 shares of the biopharmaceutical company’s stock worth $1,789,000 after buying an additional 817,050 shares during the period. Institutional investors own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.